Genelux Corporation Common Stock (GNLX) Stock Analysis

Genelux Corporation Common Stock (GNLX) is a publicly traded company in the HEALTHCARE sector. It trades at $2.95, carries a market capitalization of $133.18M. This page summarizes the public market data, fundamentals, and frequently asked questions for GNLX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.95
• Market Cap: $133.18M
• EPS: $-0.85
• 52-Week High: $8.54
• 52-Week Low: $2.29

Market Sentiment

Genelux Corporation Common Stock currently has a Neutral sentiment score of 0.06.

About Genelux Corporation Common Stock

Genelux Corporation (GNLX) is a clinical-stage biopharmaceutical company based in Westlake Village, California, focused on developing cutting-edge oncolytic viral immunotherapies for aggressive solid tumors. The company utilizes its proprietary technology platform to create innovative treatments that activate and enhance the immune response against cancer, aiming to improve overall patient outcomes in oncology. With a promising pipeline of therapies, Genelux is well-positioned to impact the i...

GNG Research Analysis

GNG Research scores Genelux Corporation Common Stock (GNLX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GNLX.

Frequently Asked Questions

Does GNLX pay dividends?

Genelux Corporation Common Stock (GNLX) does not currently pay a regular dividend.

What is GNLX's market cap?

Genelux Corporation Common Stock (GNLX) has a market capitalization of $133.18M with a current stock price of $2.95.